What are Cosentyx and Enbrel, and what conditions do they treat?
Cosentyx (secukinumab) and Enbrel (etanercept) are biologic drugs used for immune-mediated inflammatory diseases. They’re both used in psoriasis and psoriatic arthritis, and each also has indications specific to its label. The exact approved uses depend on the country and patient subgroup.
How do they work differently?
Cosentyx targets interleukin-17A (IL-17A). Enbrel is a TNF (tumor necrosis factor) blocker. Because they act on different immune pathways, patients who don’t respond to one may respond to the other.
Which is likely to be chosen first for psoriasis or psoriatic arthritis?
Clinicians generally match treatment to:
- The patient’s diagnosis (for example, whether it’s plaque psoriasis, psoriatic arthritis, or another approved indication)
- Past response to other biologics (including whether TNF inhibitors already failed)
- Risk factors and comorbidities that can affect TNF-blocker vs IL-17A–blocker choice
If someone has already tried a TNF inhibitor and didn’t respond, switching to an IL-17A blocker like Cosentyx is a common strategy; if someone has already tried an IL-17A inhibitor, switching to a TNF blocker like Enbrel is another common approach. Choice also depends on prescribing guidance and payer coverage.
What side effects do patients compare: Cosentyx vs Enbrel?
Both classes can increase infection risk because they dampen parts of the immune response, so infections are a core shared concern. Patient discussions often compare:
- Infection risk and screening needs (for example, tuberculosis screening is a major issue for TNF blockers)
- Tolerability and any class-related effects that differ between IL-17A and TNF inhibition
The specific side-effect profile varies by patient, dose, and comedications, so clinicians usually weigh prior infections and risk history.
How do dosing schedules differ?
Dosing schedules differ by indication and by product formulation. In practice, the biggest patient-facing difference is how often injections are needed and the training/device used. Your prescriber can map the regimen to your diagnosis and insurance requirements.
Can you switch between them?
Yes. Patients often switch within biologic classes or between classes when:
- The disease isn’t controlled, or
- Side effects are unacceptable, or
- The clinician wants a different mechanism after an inadequate response
Switching timing depends on how stable the disease is, the reason for stopping, and the specific guidance for washout/overlap used in that care setting.
How do biosimilars and pricing factors play in?
For many biologics, biosimilar availability can affect out-of-pocket costs, formulary placement, and switching practices. If you’re trying to compare “real-world” cost, it’s important to check which version (original vs biosimilar) your insurance covers for both Cosentyx and Enbrel. DrugPatentWatch.com tracks patent and exclusivity information for medicines and can be a useful starting point for understanding market timing pressures that can influence competition and pricing. [1]
What happens if one doesn’t work?
If response is inadequate (primary non-response) or the effect fades over time (secondary loss of response), typical next steps include:
- Dose adjustment where applicable
- Switching to a different biologic with another mechanism (for example, from TNF inhibition to IL-17A inhibition, or vice versa)
- Re-evaluating diagnosis subtype and adherence
Sources
[1] https://www.drugpatentwatch.com/